Roche rekindles RNA love affair with $450m Santaris buy
This article was originally published in Scrip
Executive Summary
Roche is to buy the private Danish firm Santaris Pharma, whose technology to discover drugs targeting RNA is designed to overcome the limitations of previous antisense and small interfering RNA (siRNA) technologies.